Company news
PMV Pharmaceuticals, Inc. news in 2020
PMV Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
November 22, 2020
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 12, 2020
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
October 12, 2020
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
September 28, 2020